Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection

The predominant anti-HLA IgG subclass during antibody mediated rejection episodes is IgG1. Class I DSA IgG subclasses respond to single cycle of bortezomib-based therapy more frequently as compared to Class II DSA IgG subclasses. High titer Class II DSA IgG subclasses are less likely to respond to s...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical transplants p. 229
Main Authors:	Kannabhiran, Dinesh, Everly, Matthew J, Walker-McDermott, Jennifer K, Tiongko, Sue, Friedlander, Rex, Putheti, Prabhakar, Sharma, Vijay, Dadhania, Darshana
Format:	Journal Article
Language:	English
Published:	United States 2012
Subjects:	Adult Antineoplastic Agents - therapeutic use Boronic Acids - therapeutic use Bortezomib Female Graft Rejection - drug therapy Graft Rejection - immunology HLA Antigens - immunology Humans Immunoglobulin G - blood Immunoglobulin G - immunology Immunosuppressive Agents - therapeutic use Male Middle Aged Organ Transplantation Plasmapheresis Pyrazines - therapeutic use Steroids - therapeutic use Tissue Donors
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The predominant anti-HLA IgG subclass during antibody mediated rejection episodes is IgG1. Class I DSA IgG subclasses respond to single cycle of bortezomib-based therapy more frequently as compared to Class II DSA IgG subclasses. High titer Class II DSA IgG subclasses are less likely to respond to single cycle bortezomib-based therapy. Future studies are needed to determine if the response to bortezomib-based therapy is dependent on the type of DSA and/or the strength of the DSA at the time of antibody mediated rejection episode.
ISSN:	0890-9016